{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:29Z","timestamp":1792001549022,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) serology in the first trimester (T1) of pregnancy relies on immunoglobulin (Ig) G (IgG) and IgM testing, followed by IgG avidity measurement when both IgG and IgM are positive. Valacyclovir is proposed to prevent vertical transmission in maternal primary infection (MPI) during T1. Our objective was to assess the risk of transmission, with and without valacyclovir, based on IgG avidity values and MPI timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cases (2012\u20132024) with positive or equivocal IgM, intermediate or low IgG avidity (VIDAS and\/or LIAISON) in T1, and a CMV PCR performed in amniotic fluid were retrieved from the laboratory software. The MPI date was estimated using a logarithmic model based on VIDAS avidity results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five hundred and sixty one women (58% untreated, 42% treated) were included. In cases with low avidity and no treatment, transmission was 34% and 31% with VIDAS and LIAISON assays, respectively. Intermediate avidities and no treatment were also associated with high transmission rates (14% and 22%). VIDAS avidity values \u22650.60 or \u22650.50 in samples collected before 12 weeks were associated with 0% and 5% transmission rates, respectively. Without treatment, transmission occurred in 26% (9\/34) of women with a LIAISON avidity value between 0.250 and 0.350. Valacyclovir significantly reduced transmission to 2%, 5%, and 16% in preconceptional, periconceptional, and T1 periods, respectively (P = .034, .003, and &amp;lt;.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that the LIAISON threshold for high avidity should be &amp;gt;0.250. Except for VIDAS avidity values \u22650.60 before 12 weeks, treatment is beneficial for women with positive IgM and low\/intermediate avidity, regardless of MPI timing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf437","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T11:42:06Z","timestamp":1754134926000},"page":"e417-e423","source":"Crossref","is-referenced-by-count":6,"title":["Cytomegalovirus Vertical Transmission Rate According to IgG Avidity Value and Valacyclovir Treatment of Maternal Primary Infection in the First Trimester of Pregnancy"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3631-184X","authenticated-orcid":false,"given":"Jacques","family":"Fourgeaud","sequence":"first","affiliation":[{"name":"Virology Unit\u2014National Reference Laboratory for Herpes Viruses\u2014H\u00f4pital Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris (AP-HP) , Paris ,","place":["France"]},{"name":"F\u00e9d\u00e9ration pour la recherche en explorations et th\u00e9rapeutiques innovantes in utero (FETUS), Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariame","family":"Barry","sequence":"additional","affiliation":[{"name":"Virology Unit\u2014National Reference Laboratory for Herpes Viruses\u2014H\u00f4pital Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bourgon","sequence":"additional","affiliation":[{"name":"Obstetrics, Fetal Medicine Surgery and Imaging Unit\u2014H\u00f4pital Necker Enfants Malades, GHU Paris Centre, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veyrenche","sequence":"additional","affiliation":[{"name":"Virology Unit\u2014National Reference Laboratory for Herpes Viruses\u2014H\u00f4pital Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris (AP-HP) , Paris ,","place":["France"]},{"name":"F\u00e9d\u00e9ration pour la recherche en explorations et th\u00e9rapeutiques innovantes in utero (FETUS), Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Guilleminot","sequence":"additional","affiliation":[{"name":"Virology Unit\u2014National Reference Laboratory for Herpes Viruses\u2014H\u00f4pital Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris (AP-HP) , Paris ,","place":["France"]},{"name":"F\u00e9d\u00e9ration pour la recherche en explorations et th\u00e9rapeutiques innovantes in utero (FETUS), Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Ville","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration pour la recherche en explorations et th\u00e9rapeutiques innovantes in utero (FETUS), Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Obstetrics, Fetal Medicine Surgery and Imaging Unit\u2014H\u00f4pital Necker Enfants Malades, GHU Paris Centre, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leruez-Ville","sequence":"additional","affiliation":[{"name":"Virology Unit\u2014National Reference Laboratory for Herpes Viruses\u2014H\u00f4pital Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris (AP-HP) , Paris ,","place":["France"]},{"name":"F\u00e9d\u00e9ration pour la recherche en explorations et th\u00e9rapeutiques innovantes in utero (FETUS), Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025122403243076100_ciaf437-B1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ajog.2020.02.018","article-title":"Cytomegalovirus infection during pregnancy: state of the science","volume":"223","author":"Leruez-Ville","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2025122403243076100_ciaf437-B2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1471-0528.2009.02139.x","article-title":"A 2-year study on cytomegalovirus infection during pregnancy in a French hospital","volume":"116","author":"Picone","year":"2009","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"2025122403243076100_ciaf437-B3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2025122403243076100_ciaf437-B4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"2025122403243076100_ciaf437-B5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/uog.23685","article-title":"Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy","volume":"58","author":"Faure-Bardon","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025122403243076100_ciaf437-B6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/uog.26039","article-title":"New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus","volume":"61","author":"Egloff","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025122403243076100_ciaf437-B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajog.2023.07.022","article-title":"The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis","volume":"230","author":"Chatzakis","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2025122403243076100_ciaf437-B8","doi-asserted-by":"crossref","first-page":"105614","DOI":"10.1016\/j.jcv.2023.105614","article-title":"Comparison of two serological screening strategies for cytomegalovirus primary infection in the first trimester of pregnancy","volume":"169","author":"Fourgeaud","year":"2023","journal-title":"J Clin Virol"},{"key":"2025122403243076100_ciaf437-B9","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.lanepe.2024.100892","article-title":"Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European Congenital Infection Initiative (ECCI)","volume":"40","author":"Leruez-Ville","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025122403243076100_ciaf437-B10","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/JCM.02172-08","article-title":"Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays","volume":"47","author":"Lagrou","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2025122403243076100_ciaf437-B11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcv.2012.10.017","article-title":"Re-evaluation of the VIDAS(\u00ae) cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation","volume":"56","author":"Vauloup-Fellous","year":"2013","journal-title":"J Clin Virol"},{"key":"2025122403243076100_ciaf437-B12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10096-014-2080-4","article-title":"Clinical evaluation of the Roche Elecsys CMV IgG avidity assay","volume":"33","author":"Vauloup-Fellous","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025122403243076100_ciaf437-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2015.09.002","article-title":"Evaluation of the new LIAISON(\u00ae) CMV IgG, IgM and IgG avidity II assays","volume":"72","author":"Delforge","year":"2015","journal-title":"J Clin Virol"},{"key":"2025122403243076100_ciaf437-B14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/cid\/ciy166","article-title":"Cytomegalovirus shedding in seropositive pregnant women from a high-seroprevalence population: the Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study","volume":"67","author":"Barbosa","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025122403243076100_ciaf437-B15","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.cmi.2021.09.013","article-title":"Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcome","volume":"28","author":"Zelini","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025122403243076100_ciaf437-B16","doi-asserted-by":"crossref","first-page":"100560","DOI":"10.1016\/j.ajogmf.2021.100560","article-title":"Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women","volume":"4","author":"Gatta","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2025122403243076100_ciaf437-B17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/pd.5107","article-title":"Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks\u2019 threshold","volume":"37","author":"Enders","year":"2017","journal-title":"Prenat Diagn"},{"key":"2025122403243076100_ciaf437-B18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/526499","article-title":"Human cytomegalovirus (HCMV) DNAemia in the mother at amniocentesis as a risk factor for iatrogenic HCMV infection of the fetus","volume":"197","author":"Revello","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf437\/63962246\/ciaf437.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e417\/63962246\/ciaf437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e417\/63962246\/ciaf437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:24:38Z","timestamp":1766564678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/5\/e417\/8222862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf437","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,8,6]]}}}